Midkine expression is associated with clinicopathological features and BRAF mutation in papillary thyroid cancer
- 23 November 2013
- journal article
- research article
- Published by Springer Nature in Endocrine
- Vol. 46 (2) , 285-291
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Diagnostic biomarkers of differentiated thyroid cancerEndocrine, 2013
- Midkine Promotes Neuroblastoma through Notch2 SignalingCancer Research, 2013
- Expression of midkine and endoglin in breast carcinomas with different immunohistochemical profilesAPMIS, 2010
- Evaluation of midkine and anterior gradient 2 in a multimarker panel for the detection of ovarian cancerJournal of Experimental & Clinical Cancer Research, 2010
- Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid CancerThyroid®, 2009
- BRAF Mutation in Papillary Thyroid Cancer: Pathogenic Role, Molecular Bases, and Clinical ImplicationsEndocrine Reviews, 2007
- Increasing Incidence of Thyroid Cancer in the United States, 1973-2002JAMA, 2006
- BRAF mutation in thyroid cancerEndocrine-Related Cancer, 2005
- Immunohistochemical and In Situ Hybridization Analyses of Midkine Expression in Thyroid Papillary CarcinomaLaboratory Investigation, 2000
- Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancerThe American Journal of Medicine, 1994